Lexaria Bioscience Corp (LEXXW) - Net Assets
Based on the latest financial reports, Lexaria Bioscience Corp (LEXXW) has net assets worth $4.52 Million USD as of November 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.05 Million) and total liabilities ($1.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Lexaria Bioscience Corp (LEXXW) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.52 Million |
| % of Total Assets | 74.76% |
| Annual Growth Rate | 4.45% |
| 5-Year Change | -80.08% |
| 10-Year Change | 2865.87% |
| Growth Volatility | 672.81 |
Lexaria Bioscience Corp - Net Assets Trend (2005–2025)
This chart illustrates how Lexaria Bioscience Corp's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Lexaria Bioscience Corp for the complete picture of this company's asset base.
Annual Net Assets for Lexaria Bioscience Corp (2005–2025)
The table below shows the annual net assets of Lexaria Bioscience Corp from 2005 to 2025. For live valuation and market cap data, see Lexaria Bioscience Corp market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-08-31 | $2.60 Million | -66.02% |
| 2024-08-31 | $7.66 Million | +185.78% |
| 2023-08-31 | $2.68 Million | -64.89% |
| 2022-08-31 | $7.63 Million | -41.57% |
| 2021-08-31 | $13.06 Million | +426.28% |
| 2020-08-31 | $2.48 Million | -0.34% |
| 2019-08-31 | $2.49 Million | +4.29% |
| 2018-08-31 | $2.39 Million | -13.72% |
| 2017-08-31 | $2.77 Million | +3053.97% |
| 2016-08-31 | $87.76K | -86.63% |
| 2015-08-31 | $656.60K | -68.72% |
| 2014-08-31 | $2.10 Million | 0.00% |
| 2013-08-31 | $2.10 Million | -5.67% |
| 2012-08-31 | $2.23 Million | -16.39% |
| 2011-08-31 | $2.66 Million | +11.42% |
| 2010-08-31 | $2.39 Million | +8.32% |
| 2009-08-31 | $2.21 Million | -10.43% |
| 2008-08-31 | $2.46 Million | -27.48% |
| 2007-08-31 | $3.39 Million | +381.85% |
| 2006-08-31 | $704.55K | -35.32% |
| 2005-08-31 | $1.09 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lexaria Bioscience Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6338489100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (August 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $19.56K | 0.65% |
| Other Comprehensive Income | $-70.33K | -2.35% |
| Other Components | $66.50 Million | 2224.34% |
| Total Equity | $2.99 Million | 100.00% |
Lexaria Bioscience Corp Competitors by Market Cap
The table below lists competitors of Lexaria Bioscience Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Clene Inc
NASDAQ:CLNNW
|
$16.32 |
|
Hall of Fame Village LLC
NASDAQ:HOFVW
|
$17.52 |
|
Ordinary Fully Paid Deferred Settlement
AU:1TTDB
|
$20.45 |
|
Arko Corp
NASDAQ:ARKOW
|
$23.76 |
|
Aquis Exchange PLC
LSE:AQX
|
$10.66 |
|
BriaCell Therapeutics Corp
NASDAQ:BCTXW
|
$8.89 |
|
Ucommune International Ltd
NASDAQ:UKOMW
|
$6.51 |
|
immatics biotechnologies GmbH
NASDAQ:IMTXW
|
$5.68 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lexaria Bioscience Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,036,400 to 2,989,697, a change of -5,046,703 (-62.8%).
- Net loss of 11,901,841 reduced equity.
- New share issuances of 6,046,163 increased equity.
- Other comprehensive income decreased equity by 50,519.
- Other factors increased equity by 859,494.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.90 Million | -398.1% |
| Share Issuances | $6.05 Million | +202.23% |
| Other Comprehensive Income | $-50.52K | -1.69% |
| Other Changes | $859.49K | +28.75% |
| Total Change | $- | -62.80% |
Book Value vs Market Value Analysis
This analysis compares Lexaria Bioscience Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-08-31 | $6.81 | $0.00 | x |
| 2006-08-31 | $4.38 | $0.00 | x |
| 2007-08-31 | $16.76 | $0.00 | x |
| 2008-08-31 | $11.23 | $0.00 | x |
| 2009-08-31 | $8.21 | $0.00 | x |
| 2010-08-31 | $5.29 | $0.00 | x |
| 2011-08-31 | $5.40 | $0.00 | x |
| 2012-08-31 | $3.69 | $0.00 | x |
| 2013-08-31 | $0.13 | $0.00 | x |
| 2014-08-31 | $0.08 | $0.00 | x |
| 2015-08-31 | $0.58 | $0.00 | x |
| 2016-08-31 | $0.18 | $0.00 | x |
| 2017-08-31 | $1.53 | $0.00 | x |
| 2018-08-31 | $1.01 | $0.00 | x |
| 2019-08-31 | $0.92 | $0.00 | x |
| 2020-08-31 | $0.91 | $0.00 | x |
| 2021-08-31 | $3.02 | $0.00 | x |
| 2022-08-31 | $1.35 | $0.00 | x |
| 2023-08-31 | $0.46 | $0.00 | x |
| 2024-08-31 | $0.65 | $0.00 | x |
| 2025-08-31 | $0.17 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lexaria Bioscience Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -398.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1686.00%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.40x
- Recent ROE (-398.10%) is below the historical average (-123.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -46.66% | -2502.86% | 0.02x | 1.01x | $-617.19K |
| 2006 | -149.87% | -417.10% | 0.09x | 3.86x | $-1.13 Million |
| 2007 | -28.82% | -108.63% | 0.24x | 1.12x | $-1.32 Million |
| 2008 | -30.61% | -178.59% | 0.13x | 1.32x | $-999.77K |
| 2009 | -25.05% | -152.42% | 0.11x | 1.55x | $-772.99K |
| 2010 | -22.53% | -47.47% | 0.29x | 1.62x | $-777.09K |
| 2011 | -9.45% | -18.52% | 0.31x | 1.63x | $-517.64K |
| 2012 | -15.44% | -31.30% | 0.30x | 1.66x | $-566.07K |
| 2013 | -16.37% | -31.30% | 0.31x | 1.70x | $-553.44K |
| 2014 | -89.15% | -170.50% | 0.31x | 1.70x | $-2.08 Million |
| 2015 | -229.22% | -12042.58% | 0.02x | 0.92x | $-1.85 Million |
| 2016 | -456.60% | -2983.38% | 0.07x | 2.13x | $-1.24 Million |
| 2017 | -62.18% | -2937.31% | 0.02x | 0.95x | $-2.17 Million |
| 2018 | -276.31% | -1522.97% | 0.18x | 1.02x | $-6.84 Million |
| 2019 | -172.02% | -1841.53% | 0.08x | 1.12x | $-4.34 Million |
| 2020 | -155.79% | -1249.71% | 0.11x | 1.12x | $-4.19 Million |
| 2021 | -30.36% | -557.19% | 0.05x | 1.00x | $-5.35 Million |
| 2022 | -91.45% | -2846.30% | 0.03x | 0.99x | $-8.06 Million |
| 2023 | -218.94% | -2946.36% | 0.07x | 1.01x | $-6.97 Million |
| 2024 | -72.11% | -1248.25% | 0.05x | 1.10x | $-6.60 Million |
| 2025 | -398.10% | -1686.00% | 0.17x | 1.40x | $-12.20 Million |
Industry Comparison
This section compares Lexaria Bioscience Corp's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lexaria Bioscience Corp (LEXXW) | $4.52 Million | -46.66% | 0.34x | $11.02 |
| Advent Technologies Holdings Inc (ADNWW) | $130.20 Million | -15.76% | 0.25x | $27.01 |
| AmpliTech Group Inc (AMPGW) | $91.07K | -845.48% | 3.88x | $751.88 |
| Arko Corp (ARKOW) | $72.92 Million | -5.21% | 3.05x | $23.76 |
| Aris Mining Corporation (ARMN) | $-623.73K | 0.00% | 0.00x | $3.93 Billion |
| Aberdeen Standard Global Infrastructure Income Fund (ASGI) | $172.37 Million | 0.00% | 0.01x | $472.62 Million |
| Atlas Corp (ATCOL) | $523.44 Million | 2.74% | 0.24x | $249.71K |
| Auddia Inc (AUUDW) | $9.41 Million | -232.98% | 0.02x | $394.90 |
| BriaCell Therapeutics Corp (BCTXW) | $11.79 Million | -9.15% | 0.05x | $8.89 |
| Blaize Holdings, Inc. Warrants (BZAIW) | $-70.54 Million | 0.00% | 0.00x | $4.00 Million |
| Churchill Capital Corp IX Warrant (CCIXW) | $6.04K | -313.77% | 9.82x | $14.04 Million |
About Lexaria Bioscience Corp
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall … Read more